Skip to main content
Clinical Trials/NCT01417663
NCT01417663
Completed
Phase 2

Combining Exercise Training With a Drug to Break AGE-crosslinks; Effects on Cardiovascular Structure and Function and Related Mechanisms

Radboud University Medical Center1 site in 1 country48 target enrollmentNovember 2008

Overview

Phase
Phase 2
Intervention
Alt-711
Conditions
Cardiovascular Disease
Sponsor
Radboud University Medical Center
Enrollment
48
Locations
1
Primary Endpoint
Examine the combined effects of one year exercise training and the AGE-crosslink breaker Alagebrium on vascular endothelial function.
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Healthy but sedentary aging leads to increased morbidity and mortality of cardiovascular disease. This is partly due to the accumulation of Advanced Glycation Endproducts (AGEs) and the stiffening of the myocardium and arteries. New medication has been developed to break these AGE-crosslinks to improve cardiovascular compliance. The positive influence of regular physical activity is well known for cardiovascular disease and aging. Therefore, what is the most effective intervention, physical exercise and/or new medication AGE-crosslink breakers, in improving the cardiovascular and cerebrovascular compliance and improving the endothelial function in healthy sedentary elderly.

Registry
clinicaltrials.gov
Start Date
November 2008
End Date
June 2011
Last Updated
12 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Maria Hopman

Prof.Dr. M.T.E. Hopman

Radboud University Medical Center

Eligibility Criteria

Inclusion Criteria

  • Healthy sedentary elderly
  • Age 65 yrs and older

Exclusion Criteria

  • Cardiovascular disease
  • Cerebrovascular disease
  • Changes on ECG indicating cardiomyopathy or ischemia
  • No cardiovascular medication
  • Diabetes Mellitus
  • Hypercholesterolemia
  • BMI \> 33 kg/m2
  • Intensive exercise \> 1 hour a week

Arms & Interventions

Alagebrium

In this study there will be four different groups: One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training

Intervention: Alt-711

Alagebrium

In this study there will be four different groups: One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training

Intervention: Physical exercise training

Exercise training

In this study there will be four different groups: One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training

Intervention: Alt-711

Exercise training

In this study there will be four different groups: One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training

Intervention: Physical exercise training

Outcomes

Primary Outcomes

Examine the combined effects of one year exercise training and the AGE-crosslink breaker Alagebrium on vascular endothelial function.

Time Frame: 0 and 12 months

At baseline and 12 months the endothelial function will be measured with an invasive vascular function measurement using the leg model. Via an arterial line in the common femoral artery acethylcholine, sodium nitroprusside and LNMMA will be infused at different dosages. Vascular response will be measured using venous occlusion plethysmography. Non-invasive vascular measurements, e.g.flow mediated dilation and pulse wave velocity, using ultrasound techniques will be performed at 0, 6 and 12 months. Also, cardiopulmonary fitness level will be tested at 0, 3, 6 and 12 months with an ergometer.

Secondary Outcomes

  • Examine the individual effects of one year exercise training and the AGE-crosslink breaker Alagebrium on vascular endothelial function.(0 and 12 months)
  • Examine the combined effects of one year exercise training and the AGE-crosslink breaker Alagebrium on cardiac function.(0, 6 and 12 months)
  • Examine the individual effects of one year exercise training and the AGE-crosslink breaker Alagebrium on cardiac function.(0, 6 and 12 months)
  • Examine the combined effects of one year exercise training and the AGE-crosslink breaker Alagebrium on cerebral perfusion and cognitive function.(0 and 12 months)
  • Examine the individual effects of one year exercise training and the AGE-crosslink breaker Alagebrium on cerebral perfusion and cognitive function.(0 and 12 months)

Study Sites (1)

Loading locations...

Similar Trials